Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Ibogaine for Parkinson's: A Groundbreaking Treatment at MindScape Retreat in Cozumel, Mexico


News provided by

MindScape Retreat- Ibogaine Treatment Center

Mar 14, 2025, 10:35 ET

Share this article

Share toX

Share this article

Share toX

Ibogaine for Parkinsons
Ibogaine for Parkinsons

A Revolutionary Approach to Neurodegeneration

MIAMI, March 14, 2025 /PRNewswire-PRWeb/ -- Parkinson's disease (PD) is a chronic, progressive neurological disorder that affects millions worldwide. It disrupts motor function, cognitive abilities, and emotional well-being, leaving individuals struggling with tremors, stiffness, and a declining quality of life. Traditional treatments such as Levodopa only offer temporary symptom relief while failing to halt neurodegeneration or repair dopamine-producing neurons.

At MindScape Retreat, a licensed Ibogaine treatment center located on the serene island of Cozumel, Mexico, we offer a breakthrough alternative—Ibogaine therapy for Parkinson's disease. This plant-based neurotherapeutichas shown promising results in restoring dopamine function, promoting neurogenesis, and improving overall neurological health.

Why Parkinson's Patients Are Turning to Ibogaine Therapy

Parkinson's disease primarily stems from the loss of dopamine-producing neurons in the substantia nigra, which leads to:

  • Tremors, rigidity, and loss of motor control
  • Cognitive impairment, memory loss, and brain fog
  • Depression, anxiety, and sleep disturbances
  • Progressive decline in independence and mobility

While medications help manage symptoms, they do not address the root cause of the disease. Ibogaine offers a different approach—one that focuses on repairing and protecting neurons rather than just masking symptoms.

How Ibogaine Works to Restore Neurological Function

1. Stimulating Neurogenesis & Repairing Dopaminergic Neurons

Ibogaine increases Glial-Derived Neurotrophic Factor (GDNF), a critical protein that:

  • Protects and regenerates dopamine-producing neurons
  • Encourages the growth of new neurons and synaptic connections
  • Slows or even reverses neurodegeneration

This is a game-changer for Parkinson's patients, as no conventional treatments promote neuronal repair the way Ibogaine does.

2. Enhancing Cognitive Function & Brain Plasticity

Cognitive decline is a major concern for those with Parkinson's. Ibogaine stimulates Brain-Derived Neurotrophic Factor (BDNF), which:

  • Boosts memory, focus, and mental clarity
  • Supports brain plasticity, helping the brain adapt and heal
  • Reduces brain fog and cognitive impairments linked to Parkinson's

3. Restoring Dopamine Balance & Improving Motor Function

Parkinson's symptoms are primarily due to dopamine depletion. Ibogaine naturally restores dopamine function by:

  • Modulating dopamine transporters (DAT), enhancing dopamine uptake
  • Increasing dopamine receptor sensitivity, improving motor control
  • Reducing tremors, muscle stiffness, and balance issues

This helps Parkinson's patients regain movement, energy, and mental clarity without relying solely on pharmaceuticals.

4. Reducing Neuroinflammation & Preventing Further Damage

Neuroinflammation plays a major role in Parkinson's progression. Ibogaine has strong anti-inflammatory and neuroprotective effects, including:

  • Reducing pro-inflammatory cytokines that contribute to brain cell damage
  • Modulating NMDA receptors, preventing excitotoxicity (which worsens neurodegeneration)
  • Enhancing mitochondrial function, helping neurons stay healthy and resilient

By calming neuroinflammation and oxidative stress, Ibogaine may protect against further disease progression and improve long-term brain function.

MindScape Retreat: A Leading Ibogaine Treatment Center for Parkinson's

Located 60 miles from Cancun, on the tranquil island of Cozumel, Mexico, MindScape Retreat offers a world-class Ibogaine treatment program designed specifically for neurological healing.

Why Choose MindScape Retreat?

1. Licensed & Medically Supervised Treatment

  • Comprehensive pre-treatment evaluations (EKGs, bloodwork, neurological assessments)
  • 24/7 medical supervision by neurologists and experienced medical professionals
  • Collaboration with research institutions to advance Ibogaine-based neurotherapies

2. A Holistic, Multi-Therapeutic Approach

At MindScape Retreat, we enhance Ibogaine therapy by integrating other cutting-edge neuroprotective therapies:

  • 5-MeO-DMT therapy – Facilitates emotional healing, serotonin balance, and post-Ibogaine integration
  • NAD+ infusions – Supports mitochondrial function, neurotransmitter stability, and cellular repair
  • Yoga & meditation – Reduces stress, improves motor control, and supports neurological recovery

3. Post-Treatment Support for Long-Term Recovery

  • Neurorehabilitation plans to maintain improvements in motor function & cognition
  • Emotional & psychological support to ensure long-term well-being
  • Personalized lifestyle recommendations to sustain neurological health

Scientific Evidence: Why Ibogaine is a Game-Changer for Parkinson's Disease

Studies are beginning to confirm what many Ibogaine patients have already experienced:

  • Neuroregeneration & Dopamine Repair – Research shows that Ibogaine stimulates GDNF, protecting dopaminergic neurons from further loss (Michael J. Fox Foundation, 2021).
  • Motor & Cognitive Improvements – Patients treated with Ibogaine report better movement control, reduced tremors, and improved cognitive function (Neuroscience News, 2023).
  • Anti-Inflammatory & Neuroprotective Effects – Research highlights Ibogaine's ability to reduce neuroinflammation, making it a promising long-term treatment for Parkinson's (Frontiers in Neurology, 2023).

While ongoing clinical trials continue to explore Ibogaine's full potential, real-world results at MindScape Retreat have been remarkable, with patients reporting significant improvements in mobility, cognition, and emotional health.

A New Hope for Parkinson's Patients

For decades, Parkinson's disease has been considered incurable, with treatments only managing symptoms rather than repairing the damage. Ibogaine therapy represents a new frontier in neuroregeneration, offering real hope for slowing disease progression and restoring function.

At MindScape Retreat in Cozumel, Mexico, we are committed to providing safe, effective, and research-backed Ibogaine treatment that is helping Parkinson's patients regain mobility, mental clarity, and a better quality of life.

Media Contact

Dr Calderon, MindScape Retreat- Ibogaine Treatment Center, 1 786-761-7729, [email protected], https://www.mindscaperetreat.com/ibogaine-treatment-clinic

SOURCE MindScape Retreat- Ibogaine Treatment Center

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.